Dr. Mattison chairs NAM report

Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics.  Over the past half-century – with the increasing focus on evidence based treatment the use of compounded medications substantially decreased.  However, in some therapeutic areas, such as menopause, use of compounded medications continues. 

Risk Sciences International 1

The continuation of use of compounded medications represents a challenge to the USFDA because the standard evaluations of benefit and risk are not required. 

To gain guidance in this concern the FDA asked the National Academies of Sciences, Engineering and Medicine to form a consensus committee to characterize the clinical utility of compounded bioidentical hormone therapy. 

The committee was chaired by  Dr. Donald Mattison the Chief Medical Officer of Risk Sciences International and composed of a dozen clinicians and scientists who worked together over the course of 1.5 years to pull the literature on risk-benefit, and clinical utility of compounded bioidentical hormone therapy.  The publication can be downloaded here.

The committee concluded (Conclusion 9.1) that there is insufficient evidence to support the overall clinical utility of compounded bioidentical hormone therapy as treatment for menopause and male hypogonadism symptoms. 

Posted in

More RSI News

Risk of Myocarditis and Pericarditis

May 11, 2022
RSI logo in white

Using data from the US Centers for Disease Control (CDC) Vaccine Adverse Event Reporting System, RSI investigators collaborated on a study showing increased risks of…

Read News Item

Quinolones and risk of retinal detachment

April 26, 2022
Quinolones

Following previous work on the potential risk of acute liver failure associated with quinolone antibiotics, RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel…

Read News Item

IAI climate change report

April 12, 2022
IAI Climate Change report

The International Aluminium Institute (IAI) recently commissioned Climate Risk Institute (CRI) and Risk Sciences International (RSI) to produce a series of informational tools evaluating and…

Read News Item

Quinolones and risk of acute liver failure

April 12, 2022
Quinolones

Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski,…

Read News Item